Vicente Boix Martínez-rekin lankidetzan egindako argitalpenak (11)

2022

  1. Discovering HIV related information by means of association rules and machine learning

    Scientific Reports, Vol. 12, Núm. 1

2021

  1. Identification and validation of clinical phenotypes with prognostic implications in patients admitted to hospital with COVID-19: a multicentre cohort study

    The Lancet Infectious Diseases, Vol. 21, Núm. 6, pp. 783-792

2020

  1. Characteristics and predictors of death among 4035 consecutively hospitalized patients with COVID-19 in Spain

    Clinical Microbiology and Infection, Vol. 26, Núm. 11, pp. 1525-1536

2017

  1. Simplification to dual therapy (atazanavir/ritonavir1lamivudine) versus standard triple therapy [atazanavir/ritonavir1two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study)

    Journal of Antimicrobial Chemotherapy, Vol. 72, Núm. 1, pp. 246-253

2016

  1. Costs and cost-effectiveness analysis of 2015 GESIDA/Spanish AIDS National Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 34, Núm. 6, pp. 361-371

  2. Human immunodeficiency virus/hepatitis C virus coinfection in Spain: Prevalence and patient characteristics

    Open Forum Infectious Diseases, Vol. 3, Núm. 2

2015

  1. Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial

    The Lancet Infectious Diseases, Vol. 15, Núm. 7, pp. 775-784

  2. Executive summary of the GESIDA/National AIDS Plan Consensus Document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2015)

    Enfermedades infecciosas y microbiologia clinica

2013

  1. Análisis de costes y de coste/eficacia de las pautas preferentes de GESIDA/Plan Nacional sobre el Sida en 2013 para el tratamiento antirretroviral inicial en adultos infectados por el virus de la inmunodeficiencia humana

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 31, Núm. 9, pp. 568-578

2012

  1. Análisis de costes y de coste/eficacia de las pautas preferentes de GESIDA/Plan Nacional sobre el Sida en 2012 para el tratamiento antirretroviral inicial en adultos infectados por el virus de la inmunodeficiencia humana (VIH)

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 30, Núm. 6, pp. 283-293

2008

  1. Low rate of adverse hepatic events associated with fosamprenavir/ritonavir-based antiretroviral regimens

    HIV Clinical Trials, Vol. 9, Núm. 5, pp. 309-313